T-Knife GmbH news
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties
- Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF
BERLIN, Germany, August 06, 2020/GlobeNewswire/– T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTC
BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced they have signed an agr